Cancer Research The Future of Cancer Research: Science and Patient Impact Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suarez, B. K.
Right arrow Articles by Catalona, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suarez, B. K.
Right arrow Articles by Catalona, W. J.
[Cancer Research 61, 4982-4984, July 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Polymorphisms in the Prostate Cancer Susceptibility Gene HPC2/ELAC2 in Multiplex Families and Healthy Controls1

Brian K. Suarez2, Daniela S. Gerhard, Jennifer Lin, Beth Haberer, Loan Nguyen, Niki K. Kesterson and William J. Catalona

Departments of Psychiatry [B. K. S., D. S. G., J. L.], and Genetics [B. K. S., D. S. G., L. N., N. K. K.], and Division of Urologic Surgery [B. H., W. J. C.], Washington University, School of Medicine, St. Louis, Missouri 63110

Two polymorphisms in the newly cloned prostate cancer susceptibility gene, HPC2/ELAC2, are suspected to be associated with an increased risk of developing the disease. These missense variants result in a serine (S) to leucine (L) substitution at amino acid residue 217 and an alanine (A) to threonine (T) substitution at residue 541. We genotyped these polymorphisms in 257 multiplex prostate cancer sibships and in 355 race-matched healthy unrelated controls. A significant increase in the frequency of the T allele is seen in the prostate cancer subjects compared with controls. There is, however, little evidence for excess clustering of the T allele within the multiplex families known to be segregating this allele, and there is no evidence for linkage of prostate cancer to the HPC2/ELAC2 region of chromosome 17p11.2 in these families. The T allele shows no association with either Gleason score or age-of-onset in segregating families.




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
Y.-C. Chen, E. Giovannucci, P. Kraft, and D. J.Hunter
Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study
Carcinogenesis, May 1, 2008; 29(5): 999 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary
Molecular pathology of prostate cancer
J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
D. J. Schaid
The complex genetic epidemiology of prostate cancer
Hum. Mol. Genet., April 1, 2004; 13(90001): R103 - 121.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. L. Stanford, L. P. Sabacan, E. A. Noonan, L. Iwasaki, J. Shu, Z. Feng, and E. A. Ostrander
Association of HPC2/ELAC2 Polymorphisms with Risk of Prostate Cancer in a Population-based Study
Cancer Epidemiol. Biomarkers Prev., September 1, 2003; 12(9): 876 - 881.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. K. Nam, W. W. Zhang, J. Trachtenberg, E. Diamandis, A. Toi, M. Emami, M. Ho, J. Sweet, A. Evans, M. A.S. Jewett, et al.
Single Nucleotide Polymorphism of the Human Kallikrein-2 Gene Highly Correlates With Serum Human Kallikrein-2 Levels and in Combination Enhances Prostate Cancer Detection
J. Clin. Oncol., June 15, 2003; 21(12): 2312 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Severi, G. G. Giles, M. C. Southey, A. Tesoriero, W. Tilley, P. Neufing, H. Morris, D. R. English, M. R. E. McCredie, P. Boyle, et al.
ELAC2/HPC2 Polymorphisms, Prostate-Specific Antigen Levels, and Prostate Cancer
J Natl Cancer Inst, June 4, 2003; 95(11): 818 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
K. Q. Zhang, S. A. Salzman, D. J. Reding, B. K. Suarez, W. J. Catalona, and J. K. Burmester
Genetics of Prostate Cancer
Clin. Med. Res., January 1, 2003; 1(1): 21 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck
Inherited Genotype and Prostate Cancer Outcomes
Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Simard, M. Dumont, P. Soucy, and F. Labrie
Perspective: Prostate Cancer Susceptibility Genes
Endocrinology, June 1, 2002; 143(6): 2029 - 2040.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
V. Nwosu, J. Carpten, J. M. Trent, and R. Sheridan
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease
Hum. Mol. Genet., October 1, 2001; 10(20): 2313 - 2318.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.